US71902K1051
© Globe Newswire
07.01.2026
CERO
LISTED
NASDAQ
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
News Preview
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
News Preview
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Announces Trading on OTCQB Market
News Preview
Company’s Shares Will Continue to Trade Under Ticker CERO...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
05.11.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
News Preview
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused on patients wit...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
CERO
LISTED
NASDAQ
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
News Preview
Newly released preclinical data to be presented in a poster on November 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
News Preview
Trading of the Company’s shares of common stock on Nasdaq will be suspended at the open of trading on October 31...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
CERO
LISTED
NASDAQ
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a stem cell therapy panel titled, “A Space That is Ready to Have its Day,” at the Maxim G...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
News Preview
Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
News Preview
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
News Preview
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
News Preview
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
News Preview
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first pati...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
17.06.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
News Preview
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
News Preview
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to ef...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
News Preview
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred S...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
News Preview
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
News Preview
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
News Preview
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
News Preview
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
News Preview
SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting a poster at the American Society o...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
News Preview
SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute (SCRI) at Colorad...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
News Preview
SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuanc...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
News Preview
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
News Preview
SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces its first clinical trial site for the Company’s Phase...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
News Preview
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
News Preview
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
News Preview
Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
News Preview
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of le...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
News Preview
Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
News Preview
New poster to highlight preclinical data of CER-1236 in ovarian cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Holdings, Inc. Highlights Progress
News Preview
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
News Preview
SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its “reasonable best efforts” pub...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
News Preview
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directo...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
News Preview
Data presented as part of a poster at the SITC 2024 Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Provides Corporate Update
News Preview
Company announces submission of IND Clinical Hold Complete Response Letter...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
News Preview
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company’s management team to support recently name...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
News Preview
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
News Preview
Company anticipates near term filing of Investigational New Drug Application to FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
CERO
LISTED
NASDAQ
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
News Preview
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
